Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Double Blind Randomized Placebo Controlled Study of Trastuzumab as Short Duration Preoperative Therapy in Patients With HER2-neu Positive Operable Breast Cancer

NCT01785420 is registered in ClinicalTrials.gov with Dr Rajendra A. Badwe as lead sponsor.

NCT NCT01785420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01785420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Double Blind Randomized Placebo Controlled Study of Trastuzumab as Short Duration Preoperative Therapy in Patients With HER2-neu Positive Operable Breast Cancer
Lead sponsor
Dr Rajendra A. Badwe
Phase
Phase 3
Overall status
Terminated
Start date
May 8, 2013
Completion date
September 11, 2026
Enrollment
1,100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma breast stage i, her2 positive breast cancer